NMM
TEVA icon

Naples Money Management’s Teva Pharmaceuticals TEVA Stock Holding History

Naples Money Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$27K Hold
1,500
– – 0.02% 119
2024
Q2 		$24.5K Hold
1,500
– – 0.02% 117
2024
Q1 		$21.2K Hold
1,500
– – 0.02% 130
2023
Q4 		$15.7K Buy
+1,500
New +$14K 0.01% 159

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Naples Money Management's TEVA Position: Q3 2024 in Review

Naples Money Management held its Teva Pharmaceuticals (TEVA) position steady in Q3 2024 at 1,500 shares worth $27K. The position accounts for 0.02% of the portfolio, ranked #119.

Naples Money Management first reported a position in TEVA in Q4 2023 and has held it in 4 quarters since. 543 funds tracked by Wall St. Rank hold TEVA as of Q3 2024.

  • Naples Money Management held 1,500 shares of Teva Pharmaceuticals worth $27K as of Q3 2024.
  • Naples Money Management left its Teva Pharmaceuticals share count unchanged in Q3 2024.
  • Teva Pharmaceuticals made up 0.02% of Naples Money Management's portfolio in Q3 2024, its #119 holding.
  • Naples Money Management first reported a position in Teva Pharmaceuticals in Q4 2023 and has held it in 4 quarters since.
  • 543 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2024.

Based on Naples Money Management's 13F filing for Q3 2024, filed 12 Nov 2024.